2seventy bio, Inc.
TSVT · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.33 | -0.02 | 0.04 | -0.01 |
| FCF Yield | -4.19% | -6.16% | -4.27% | -10.98% |
| EV / EBITDA | -496.36 | -15.22 | -36.85 | -18.78 |
| Quality | ||||
| ROIC | -0.53% | -4.93% | -2.84% | -4.06% |
| Gross Margin | 77.54% | -202.22% | 57.38% | 84.99% |
| Cash Conversion Ratio | -22.77 | 0.49 | 1.06 | -0.93 |
| Growth | ||||
| Revenue 3-Year CAGR | -27.07% | -25.48% | -3.87% | -8.29% |
| Free Cash Flow Growth | -15.82% | 10.11% | 54.58% | 45.39% |
| Safety | ||||
| Net Debt / EBITDA | -178.68 | -8.04 | -15.91 | -7.47 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 3.48 | 228.60 | 68.92 | -18.34 |